Regeneron Pharmaceuticals Launches Long-Term Follow-Up Study on Gene Modified T Cell Therapy

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Study Overview: Regeneron Pharmaceuticals is initiating a long-term follow-up study titled A Long-Term Follow-up Protocol for Participants Treated With Gene Modified T Cells. The study aims to evaluate the safety and efficacy of gene modified T cell therapy in adult participants, following guidance from health authorities. This study is significant as it seeks to ensure the long-term safety of participants who have undergone gene therapy, a rapidly advancing field in medical treatments.

Intervention/Treatment: The study involves a non-interventional, observational approach focusing on participants previously treated with gene modified T cells. The primary purpose is to monitor these individuals over time without administering any new study drugs.

Study Design: This is an observational cohort study with a prospective time perspective. Participants will be monitored for safety and efficacy outcomes through scheduled assessments and patient-reported outcome questionnaires. The study does not involve any new interventions or masking procedures.

Study Timeline: The study is set to begin on August 7, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 8, 2025, indicating the study is in the planning phase and not yet recruiting participants.

Market Implications: The initiation of this study could positively influence Regeneron Pharmaceuticals’ stock performance by reinforcing investor confidence in the company’s commitment to safety and efficacy in gene therapy. As the field of gene therapy continues to grow, Regeneron’s proactive approach may set a benchmark for competitors, potentially impacting the broader industry landscape.

The study is ongoing, with further details available on the ClinicalTrials portal.